Patents Assigned to Hadasit
  • INHIBITORS OF NEUROLIGIN 4-NEUREXIN 1-BETA PROTEIN-PROTEIN INTERACTION FOR TREATMENT OF LIVER DISORDERS
    Publication number: 20190389948
    Abstract: Method for treating, attenuating and/or preventing progression of a liver disorder in a subject, the method including administering a therapeutically effective amount of an agent capable of interfering with, inhibiting and/or preventing neuroligin 4 (NLGn4)-Neurexin 1-beta (Nrx1b) protein-protein interaction; and compositions including the agent.
    Type: Application
    Filed: May 9, 2019
    Publication date: December 26, 2019
    Applicant: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
    Inventor: Rifaat SAFADI
  • Alginate compositions and uses thereof
    Patent number: 10500226
    Abstract: Compositions comprising an alginate, a source of sodium ions and a carrier (e.g., a pharmaceutically acceptable carrier), which are characterized by reduced association of the alginate chains and hence by at least one of: (i) a zeta potential weaker than ?25 mV, at a concentration of 0.5% (w/v) alginate in the carrier; and (ii) a diffusion coefficient of at least 10?8 cm2/second, at a concentration of 0.5% (w/v) alginate in the carrier, are disclosed. Also disclosed are uses of the composition and methods utilizing the composition for treating inflammatory bowel disease; liver damage, diseases and disorders, for treating a medical condition treatable by a hepatotoxic agent and for reducing or preventing liver damage, including liver damage caused by a hepatotoxic agent.
    Type: Grant
    Filed: December 30, 2013
    Date of Patent: December 10, 2019
    Assignees: Hadasit Medical Research Services and Development Ltd., B.G. Negev Technologies & Applications Ltd., at Ben-Gurion University
    Inventors: Smadar Cohen, Yaron Ilan, Eyal Shteyer, Ami Ben-Ya'Acov
  • Sustained release delivery systems for the prevention and treatment of head and neck cancers
    Patent number: 10485792
    Abstract: The present invention discloses a method of treating a head and neck cancer or preventing the development of pre-malignant lesions to this cancer, by administering locally to the oral cavity, a sustained release drug delivery system comprising a drug for the treatment of this cancer or for the prevention of said lesions, and at least one polymer, such that said system is attached to a surface in the oral cavity and remains attached thereto for at least 1 hour, accompanied by release of the drug and maintaining an effective therapeutic concentration thereof in the cavity, for at least 1 hour. Further are disclosed a sustained release drug delivery system and a liquid precursor varnish composition to this system.
    Type: Grant
    Filed: August 25, 2010
    Date of Patent: November 26, 2019
    Assignees: HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LIMITED, YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD., THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Michael Friedman, Rakefet Czernimski, Silvio Gutkind, Doron Steinberg, Irith Gati, Zakhar Nudelman
  • Use of full-length amelogenin for promoting nerve growth or regeneration
    Patent number: 10478476
    Abstract: A method of promoting nerve growth or regeneration in a subject in need thereof, wherein the subject is not afflicted with a substantial connective tissue damage, is provided. The method comprises administering to the subject a therapeutically effective amount of full-length amelogenin, thereby promoting nerve growth or regeneration in the subject.
    Type: Grant
    Filed: September 29, 2016
    Date of Patent: November 19, 2019
    Assignees: Hadasit Medical Research Services and Development Ltd., Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
    Inventors: Amir Haze, Anat Blumenfeld, Dan Deutsch
  • Anti-LPS enriched immunoglobulin for use in treatment and/or prophylaxis of fibrosis
    Patent number: 10464998
    Abstract: This invention relates to methods and compositions for treating fibrosis, by administering compositions comprising anti-LPS immunoglobulin enriched colostrum preparations. In particular, the invention relates to methods and compositions for the treatment of liver fibrosis and/or lung fibrosis. Prophylactic or therapeutic compositions and diagnostic methods are also disclosed and claimed.
    Type: Grant
    Filed: October 29, 2014
    Date of Patent: November 5, 2019
    Assignee: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LIMITED
    Inventors: Yaron Ilan, Meir Mizrahi
  • CELL COMPOSITIONS AND METHODS FOR CANCER THERAPY
    Publication number: 20190330303
    Abstract: The present invention is directed to the field of immunotherapy. Specifically, the invention provides compositions and methods for improved T cell modulation ex vivo and in vivo and for the treatment of cancer and other pathologies. More specifically, embodiments of the invention are directed to the use of soluble NTB-A polypeptides or agonists thereof for the treatment of cancer patients, for preventing and treating cytopenia in susceptible patients, and for the ex vivo preparation of improved cell compositions.
    Type: Application
    Filed: May 20, 2019
    Publication date: October 31, 2019
    Applicant: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD
    Inventors: Abraham RUTENBERG, Ronny UZANA, Michal LOTEM, Arthur MACHLENKIN, Galit EISENBERG, Tamar PERETZ-YABLONSKY, Shoshana FRANKENBURG, Roni ENGELSTEIN
  • Nitroxide radicals for the treatment of diseases of the respiratory tract
    Patent number: 10441568
    Abstract: Cyclic nitroxide compounds including, but not limited to, compounds having the general formula I: wherein the dashed line and R1-R8 are as defined herein, are disclosed herein for use in treating diseases and disorders of the respiratory tract and/or respiratory tract remodeling.
    Type: Grant
    Filed: March 24, 2016
    Date of Patent: October 15, 2019
    Assignees: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd., Hadasit Medical Research Services and Development Ltd.
    Inventors: Sara Goldstein, Amram Samuni, Neville Berkman
  • Type III deiodinase inhibitors and uses thereof
    Patent number: 10435365
    Abstract: The present invention relates to compounds that inhibit the activity of Type III deiodinase (DIO3). The present invention further relates to methods for treating or preventing depression, depression associated with other psychiatric or general medical diseases or conditions, condition amenable to treatment with known anti-depressants and cancer, particularly by using the compounds of the invention.
    Type: Grant
    Filed: March 16, 2015
    Date of Patent: October 8, 2019
    Assignees: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD., INDIAN INSTITUTE OF SCIENCE
    Inventors: Bernard Lerer, Mugesh Govindasamy, Tzuri Lifschytz
  • METHOD OF OBTAINING TERMINALLY DIFFERENTIATED NEURONAL LINEAGES AND USES THEREOF
    Publication number: 20190264172
    Abstract: Provided is a method of inducing transdifferentiation of mesenchymal stem cells (MSC), the method including (a) culturing MSC in a first culture medium including a growth factor selected for allowing formation of neuralized MSC (NMSC); (b) allowing the NMSC to proliferate for a sufficient time during which said culture medium is renewed at least once; and (c) culturing the NMSC of (b) in a second culture media including cerebrospinal fluid (CSF) for a time sufficient for the NMSC to differentiate into a population of cells including terminally differentiated neurons, astrocytes and oligodendrocytes. Also provided by the present invention is the use of MSC or NMSC for providing a composition including said population and to kits including MSC or NMSC and instructions for use of same.
    Type: Application
    Filed: May 13, 2019
    Publication date: August 29, 2019
    Applicant: Hadasit Medical Research Services & Development Limited
    Inventors: Dimitrios KARUSSIS, Ibrahim KASSIS
  • miR-122* as an active micro-RNA, compositions comprising the same and uses thereof
    Patent number: 10392617
    Abstract: The present invention provides miR-122* as a functional microRNA molecule, compositions comprising the same and uses thereof for treatment of various conditions, such as, cancer. Further provided are methods for increasing the expression, stability and/or activity of p53 in a target cell or method for inducing cancer cell death, the methods comprising introducing into the cell a miR-122* polynucleotide molecule or a vector expressing or encoding the same.
    Type: Grant
    Filed: January 6, 2015
    Date of Patent: August 27, 2019
    Assignee: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
    Inventors: Hilla Giladi, Alina Simerzin, Yael Hantz, Sagit Arbel Alon, Eithan Galun
  • COMBINATIONS OF BETA-GLYCOLIPIDES AND 4-[(2-AMINO-3,5-DIBROMOPHENYL)METHYLAMINO]CYCLOHEXAN-1-OL, COMPOSITIONS AND USES THEREOF IN THE TREATMENT OF DISORDERS ASSOCIATED WITH PROTEIN MISFOLDING AND PROTEIN AGGREGATIONS
    Publication number: 20190254992
    Abstract: Provided are therapeutic combinations of beta-glycolipides and 4-[(2-amino-3,5-dibromophenyl)methylamino]cyclohexan-1-ol, as well as compositions, kits and methods using the same in treating disorders associated with protein misfolding and for immunomodulation.
    Type: Application
    Filed: June 29, 2017
    Publication date: August 22, 2019
    Applicants: HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LIMITED, SHAARE ZEDEK SCIENTIFIC LTD.
    Inventors: David ARKADIR, Yaron ILAN, Ari ZIMRAN
  • COMPOSITIONS AND METHODS FOR INDUCING THROMBOPOIESIS
    Publication number: 20190247464
    Abstract: Methods of inducing thrombopoiesis and/or treating thrombocytopenia in a subject are provided. Accordingly there is provided a method comprising contacting stem cells with a differentiation potential towards platelets or hematopoietic progenitor cells derived therefrom with Livin, thereby inducing thrombopoiesis. Also provided is a method comprising contacting cells with a differentiation potential towards platelets with tLivin, thereby inducing thrombopoiesis. Also provided are compositions and isolated population of cells for inducing thrombopoiesis and/or treating thrombocytopenia in a subject.
    Type: Application
    Filed: April 24, 2019
    Publication date: August 15, 2019
    Applicant: Hadasit Medical Research Services and Development Ltd.
    Inventors: Dina Ben Yehuda, Ihab Abd-Elrahman, Riki Perlman, Marjorie Pick
  • TREATMENT FOR GLIOBLASTOMA
    Publication number: 20190240199
    Abstract: The invention relates to the treatment of brain tumors, specifically to improved therapy for glioblastoma utilizing specific endocrine modulators and drug combinations. The compositions and uses thereof according to the invention employ androgen receptor (AR) inhibitors, either alone or in combination with receptor tyrosine kinase inhibitors and/or chemotherapeutic agents. According to certain advantageous embodiments, the use of the AR inhibitor enzalutamide, optionally in combination with epidermal growth factor receptor inhibitors such as erlotinib and alkylating agents such as carmustine and temozolomide, is contemplated.
    Type: Application
    Filed: July 20, 2017
    Publication date: August 8, 2019
    Applicant: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
    Inventors: Iris LAVON BEN MOSHE, Tamar CANELLO AVRAMOVITCH
  • SYSTEMS AND METHODS OF AUTOMATED IN-SITU PREPARATION FOR MOUNTING OF PREFABRICATED CUSTOM DENTAL PROSTHESIS
    Publication number: 20190209274
    Abstract: A system and method of automated formation of a preparation stub, based on an a priori created computational geometrical model, configured to conform to a prefabricated fixed dental prosthesis, is described. The system includes a digital imaging facility with an image acquiring device and a three-dimensional data digitizer, a modeling facility with an exterior surface design module and an interior surface design module, a fabrication facility operatively with a computer-aided manufacturing module, as well as an application facility including an ablation tool and in-situ preparation module; application facility preferably includes an intra-oral feedbacking appliance with a distance measurement probe for automated feedback-controlled formation of a preparation stub.
    Type: Application
    Filed: December 12, 2018
    Publication date: July 11, 2019
    Applicants: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD, ROBOTOO INNOVATION LTD
    Inventors: Uri BARAK, Eyal TARAZI
  • Cell compositions and methods for cancer therapy
    Patent number: 10344073
    Abstract: Provided is directed to the field of immunotherapy. Specifically, provided are compositions and methods for improved T cell modulation ex vivo and in vivo and for the treatment of cancer and other pathologies. More specifically, embodiments of the subject matter are directed to the use of soluble NTB-A polypeptides or agonists thereof for the treatment of cancer patients, for preventing and treating cytopenia in susceptible patients, and for the ex vivo preparation of improved cell compositions.
    Type: Grant
    Filed: January 8, 2015
    Date of Patent: July 9, 2019
    Assignee: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
    Inventors: Abraham Rutenberg, Ronny Uzana, Michal Lotem, Arthur Machlenkin, Galit Eisenberg, Tamar Peretz-Yablonsky, Shoshana Frankenburg, Roni Engelstein
  • Method of obtaining terminally differentiated neuronal lineages and uses thereof
    Patent number: 10336985
    Abstract: Provided is a method of inducing transdifferentiation of mesenchymal stem cells (MSC), the method including (a) culturing MSC in a first culture medium including a growth factor selected for allowing formation of neuralized MSC (NMSC); (b) allowing the NMSC to proliferate for a sufficient time during which said culture medium is renewed at least once; and (c) culturing the NMSC of (b) in a second culture media including cerebrospinal fluid (CSF) for a time sufficient for the NMSC to differentiate into a population of cells including terminally differentiated neurons, astrocytes and oligodendrocytes. Also provided by the present invention is the use of MSC or NMSC for providing a composition including said population and to kits including MSC or NMSC and instructions for use of same.
    Type: Grant
    Filed: October 7, 2014
    Date of Patent: July 2, 2019
    Assignee: Hadasit Medical Research Services & Development Limited
    Inventors: Dimitrios Karussis, Ibrahim Kassis
  • Alginate biomaterials for the treatment of hepatic disorders
    Patent number: 10328098
    Abstract: The present invention relates to methods for the treatment of hepatic disorders in a subject in need thereof. More specifically, the methods of the invention are based on the administration, preferably, systemic administration, of a therapeutically effective amount of at least one biocompatible alginate biomaterial, any modification thereof and any combination thereof. The invention further provides methods for sustaining serum albumin levels, and/or reducing serum AST and ALT, in subjects suffering from hepatic disorder. Still further, the invention provides methods for reducing apoptosis and inducing cell proliferation in a damaged liver tissue of a subject suffering of hepatic disorder, using the alginate biomaterial described by the invention.
    Type: Grant
    Filed: July 10, 2016
    Date of Patent: June 25, 2019
    Assignees: Hadasit Medical Research Services and Development Ltd., Ben-Gurion University of the Negev Research and Development Authority
    Inventors: Yaron Ilan, Gadi Lalazar, Eyal Shteyer, Ami Ben-Ya'acov, Smadar Cohen, Tsiona Elkayam
  • Method of treatment of diseases using hoodia extracts
    Patent number: 10314873
    Abstract: A method for treating a disease comprising administering to a mammal in need thereof an effective dosage of an extract of a plant of the genus Hoodia, wherein the disease is selected from the group consisting of immune-mediated disorders, immune-associated disorders, inflammatory diseases, coronary disease, insulin resistance and liver-related diseases. In a preferred embodiment, the Hoodia is Hoodia parviflora. Also disclosed is a pharmaceutical composition for treating the above diseases comprising an effective dosage of an extract of a plant of the genus Hoodia.
    Type: Grant
    Filed: December 19, 2013
    Date of Patent: June 11, 2019
    Assignees: HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LIMITED, DESERT LABS AGRICULTURE COOPERATIVE ASSOCIATION LTD.
    Inventors: Refael Aharon, Yaron Ilan
  • METHODS AND SYSTEM FOR ASSESSING A COGNITIVE FUNCTION
    Publication number: 20190167179
    Abstract: A method of neuropsychological analysis comprises: presenting to a subject, by a user interface, a subject-specific cognitive task having at least one task portion selected from the group consisting of a time-domain task portion, a space-domain task portion, and a person-domain task portion. The method also comprises receiving responses entered by the subject using the user interface for each of the task portions, representing the responses as a set of parameters, and classifying the subject into one of a plurality of cognitive function classification groups, based on the set of parameters.
    Type: Application
    Filed: August 7, 2017
    Publication date: June 6, 2019
    Applicant: Hadasit Medical Research Services and Development Ltd.
    Inventor: Shahar ARZY
  • Compositions and methods for inducing thrombopoiesis
    Patent number: 10307462
    Abstract: Methods of inducing thrombopoiesis and/or treating thrombocytopenia in a subject are provided. Accordingly there is provided a method comprising contacting stem cells with a differentiation potential towards platelets or hematopoietic progenitor cells derived therefrom with Livin, thereby inducing thrombopoiesis. Also provided is a method comprising contacting cells with a differentiation potential towards platelets with tLivin, thereby inducing thrombopoiesis. Also provided are compositions and isolated population of cells for inducing thrombopoiesis and/or treating thrombocytopenia in a subject.
    Type: Grant
    Filed: November 6, 2014
    Date of Patent: June 4, 2019
    Assignee: Hadasit Medical Research Services and Development Ltd.
    Inventors: Dina Ben Yehuda, Ihab Abd-Elrahman, Riki Perlman, Marjorie Pick